The US Food and Drug Administration (FDA) has approved Medtronic’s Freezor and Freezor Xtra cardiac cryoablation focal catheters for the treatment of paediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).

The cardiac cryoablation catheters are designed to freeze the cardiac tissue and block unnecessary electrical signals in the heart.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic stated that the two flexible, single-use devices are the first and only ablation catheters approved by the FDA to treat AVNRT.

According to the company, nearly 35% of AVNRT cases are diagnosed in children under the age of 18.

The catheter ablation is considered to be a first-line treatment for AVNRT.

The regulatory approval for the use of Freezor and Freezor Xtra was based on data obtained from ICY-AVNRT as well as several paediatric multi-centre, randomised trials.

In these trials, the devices showed safety in the treatment of AVNRT.

The cardiac cryoablation catheters demonstrated an acute procedural success rate of 95%, with no reports of permanent pacemaker due to complete atrioventricular block in the ICY-AVNRT trials.

Medtronic cardiac ablation solutions business president Rebecca Seidel said: “We’re proud of our work with the Pediatric and Congenital Electrophysiology Society (PACES) and FDA in this first-of-its-kind, multi-stakeholder initiative to address a critical patient population.

“The shared commitment to collaborate and grow this therapy’s unique position to treat AVNRT patients demonstrates our confidence in the proven safety and efficacy of our cryoablation technology.”

The Freezor cardiac cryoablation catheter was commercially available to treat AVNRT in adults in the US for the first time in 2003 while the Freezor Xtra cardiac cryoablation catheter was available in 2016.

Last month, Medtronic’s Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator received FDA approval to treat chronic pain related to diabetic peripheral neuropathy (DPN).